Innovations

Discovery of Biomarkers (CTB2)

The TB Alliance is working with the U.S. CDC TB Trials Consortium and the AIDS Clinical Trials Group of the U.S. NIAID, NIH, to identify biomarkers for TB, which can dramatically speed the time and decrease the cost of clinical trials for new TB drugs.

Learn More

Sharing of Lab Manuals

TB Alliance is making mycolaboratory manuals from ongoing clinical trials publicly available in order to provide a useable template for other TB clinical trial organizations creating their own mycolaboratory manuals, as well as to facilitate comparison of procedures being employed across the field.

Learn More

Synergising TB Drug and Diagnostic Development

Detecting and treating TB go hand in hand. In order to most effectively and responsibly use new drug regimens, diagnostics that can detect drug-resistance are needed. Similarly, enhanced methods of detecting various forms of TB are of reduced value without appropriate treatment. TB Alliance and FIND are collaborating to harmonize development of these new tools.

Learn More

Collaborating with PDPs

Partnership is at the foundation of the TB Alliance’s operating model. With this in mind, the TB Alliance collaborates with several Product Development Partnerships (PDPs) to establish cross-PDP partnerships that foster innovation and efficiencies along with the sharing of information and resources.

Learn More

Leveraging Resources

Every dollar donated to the TB Alliance produces additional impact. The TB Alliance is committed to making its donors' contributions go as far as possible. A network of partners and series of innovative initiatives ensures maximum impact of donor funds, while helping to intensify the fight against TB.

Learn More

Open Forum Series

The Open Forum Series engages regulatory authorities around the world to identify and address crucial issues involved in advancing new TB regimens to registration, and ultimately to the people who need them.

Learn More

Global Health Research and Development Center (GHRC) of China

TB is a global problem that requires global solutions. The TB Alliance has been working with the International Scientific Exchange Foundation of China (ISEFC) in their effort to launch the Global Health Research & Development Center of China.

Learn More

Critical Path to TB Drug Regimens (CPTR)

The CPTR initiative, co-founded in part by the TB Alliance, is working to speed the introduction of impactful, new TB drug regimens.

Learn More

Regimen Development

The TB Alliance isn’t just developing drugs, but changing the way TB drug development is conducted. New TB multi-drug regimens show promise in offering dramatically faster, simpler, safer, and less toxic therapies that enable global scale-up of treatment, particularly for MDR-TB.

Learn More

Clinical Trial Sites Assessment

There are simply not enough high-quality sites that can undertake the sophisticated clinical trials needed to test new TB drugs. The TB Alliance scoured the world to find the most appropriate sites, and shared that information, so that sponsors can advance promising products in the pipeline.

Learn More

New Model to Better Understand Data from EBA and BA Trials

Research Resource: EBA and BA trials are a mainstay in the early clinical development of TB treatment regimens. TB Alliance worked with the University of Free State and Quintiles, both located in Bloemfontein, South Africa, to redefine the methodology used to analyze data for EBA and BA trials. This has resulted in a more flexible model that provides important insight into the nature of the EBA and BA of TB treatments. The partners have now made the methodology and program available to other researchers to freely use.

Learn More